Meeting
2014 ASCO Annual Meeting
RESPONSE 2: A phase 3b study evaluating the efficacy and safety of ruxolitinib in patients with hydroxyurea (HU)-resistant/intolerant polycythemia vera (PV) versus best available therapy (BAT).
Authors
Francesco Passamonti
Ospedale di Circolo e Fondazione Macchi, Varese, Italy
Francesco Passamonti , Guray Saydam , Liberata Lim , Mahmudul H Khan , Nadjat Mounedji , Martin Griesshammer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Myeloproliferative Neoplasms (MPN) and Mast Cell Disorders
Clinical Trial Registration Number
NCT02038036
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7128^)
DOI
10.1200/jco.2014.32.15_suppl.tps7128
Abstract #
TPS7128^
Poster Bd #
408B
Abstract Disclosures
Similar Posters
Poster
2011 ASCO Annual Meeting
RESPONSE: A randomized, open label, phase III study of INC424 in polycythemia vera (PV) patients resistant to or intolerant of hydroxyurea (HU).
First Author: S. Verstovsek
Poster
2024 ASCO Annual Meeting
A phase Ib, open-label study of add-on therapy with CK0804 in participants with myelofibrosis and suboptimal response to ruxolitinib.
First Author: Lucia Masarova
Poster
2023 ASCO Annual Meeting
EXCEED-ET: A single-arm multicenter study to assess the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft (P1101) in North American adults with essential thrombocythemia.
First Author: Lucia Masarova
Poster
2022 ASCO Annual Meeting
A phase 1, open-label, dose-escalation study of selinexor plus ruxolitinib in patients with treatment-naïve myelofibrosis.
First Author: Haris Ali